The U.S. government has invested more than $3
billion to stockpile medical countermeasures against bioterrorism since 2001.
The largest single acquisition has been of a first-generation anthrax vaccine
that was marketed before 2001. Stockpile quantities are sufficient to protect
first-responders and a small portion of the